Cytosorbents Corp
CTSO- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001175151
In the last 90 days, Cytosorbents Corp insiders filed 4 open-market purchases and 0 sales; 50 institutions reported holding it in 13F filings for Q2 2026, worth $6.04M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 12:36 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $8.20M (22.1% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 25, 2026 | Jan 3, 2025 | Mar 15, 2024 | Feb 1, 2023 | Jan 18, 2022 |
| Revenue | $37.1M | $35.6M | $36.3M | $34.7M | $43.2M |
| Cost of revenue | $10.6M | $10.5M | $14.0M | $14.0M | $11.0M |
| Gross profit | $26.5M | $25.1M | $22.4M | $20.7M | $32.1M |
| Operating expenses | $41.2M | $41.9M | $53.6M | $52.3M | $54.9M |
| Research and development | – | – | $15.7M | $15.1M | $16.4M |
| Selling, general and administrative | $35.6M | $35.0M | $33.6M | $34.3M | $35.8M |
| Operating income | -$14.7M | -$16.8M | -$31.2M | -$31.5M | -$22.7M |
| Income tax | -$401.0K | -$1.69M | -$813.7K | -$1.09M | -$736.0K |
| Net income | -$8.20M | -$20.7M | -$28.5M | -$32.8M | -$24.6M |
| EPS, basic | $-0.13 | $-0.38 | $-0.64 | $-0.75 | $-0.57 |
| EPS, diluted | $-0.13 | $-0.38 | $-0.64 | $-0.75 | $-0.57 |
| Weighted shares, basic | 62.2M | 54.4M | 44.7M | 43.6M | 43.4M |
| Weighted shares, diluted | 62.2M | 54.4M | 44.7M | 43.6M | 43.4M |
| Margins and growth | |||||
| Gross margin | 71.5% | 70.6% | 61.6% | 59.8% | 74.4% |
| Operating margin | -39.8% | -47.2% | -85.9% | -90.9% | -52.7% |
| Net margin | -22.1% | -58.2% | -78.4% | -94.6% | -56.9% |
| Revenue growth, year over year | +4.1% | −2.1% | +4.8% | −19.6% | +5.3% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 25, 2026 | Jan 3, 2025 | Mar 15, 2024 | Feb 1, 2023 | Jan 18, 2022 |
| Cash and equivalents | $6.25M | $3.28M | $14.1M | $22.1M | $52.1M |
| Accounts receivable | $7.55M | $7.32M | $6.06M | $5.66M | $4.52M |
| Inventory | $5.28M | $2.73M | $3.68M | $3.46M | $4.77M |
| Total current assets | $20.6M | $21.6M | $25.7M | $33.8M | $64.3M |
| Property, plant and equipment | $7.82M | $9.00M | $10.1M | $10.7M | $5.15M |
| Intangible assets | $3.23M | $3.75M | $3.91M | $4.39M | $4.70M |
| Total assets | $44.2M | $47.4M | $53.3M | $63.2M | $89.5M |
| Accounts payable | $2.87M | $3.34M | $3.80M | $1.66M | $2.81M |
| Short-term debt | – | – | $2.50M | – | – |
| Total current liabilities | $9.71M | $9.82M | $14.5M | $9.71M | $13.7M |
| Long-term debt | $16.7M | $14.0M | $2.54M | $5.00M | – |
| Total liabilities | $38.3M | $36.3M | $30.0M | $27.9M | $26.9M |
| Shareholders' equity | $5.90M | $11.1M | $23.3M | $35.4M | $62.6M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 25, 2026 | Jan 3, 2025 | Mar 15, 2024 | Feb 1, 2023 | Jan 18, 2022 |
| Operating cash flow | -$12.4M | -$14.4M | -$21.7M | -$28.2M | -$14.0M |
| Capital expenditures | $164.0K | $284.3K | $538.1K | $6.09M | $3.64M |
| Free cash flow | -$12.5M | -$14.7M | -$22.2M | -$34.3M | -$17.6M |
| Depreciation and amortization | $1.23M | $1.57M | $1.46M | $882.6K | $731.6K |
| Stock-based compensation | $2.77M | $3.76M | $3.33M | $3.42M | $4.02M |
| Investing cash flow | -$415.0K | -$669.4K | -$936.2K | -$6.46M | -$4.28M |
| Financing cash flow | $9.31M | $9.33M | $14.5M | $4.96M | $715.2K |
| Net change in cash | -$1.99M | -$5.85M | -$8.22M | -$30.0M | -$17.6M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 7.5% | 10.6% | 9.2% | 9.9% | 9.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Jul 31, 2026 | 62.8M | +0.1% | SEC |
| May 7, 2026 | 62.8M | +0.3% | SEC |
| Mar 20, 2026 | 62.7M | +0.3% | SEC |
| Nov 10, 2025 | 62.8M | +14.9% | SEC |
| Aug 1, 2025 | 62.8M | +15.3% | SEC |
| May 13, 2025 | 62.6M | +15.3% | SEC |
| Mar 31, 2025 | 62.5M | +15.1% | SEC |
| Nov 5, 2024 | 54.7M | +23.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.